Abstract Number: 0509 • ACR Convergence 2022
Guselkumab Provides Sustained Improvements in Work Productivity and Daily Activity in Patients with Active Psoriatic Arthritis Through 2 Years of DISCOVER-2
Background/Purpose: Psoriatic arthritis (PsA) impacts patients' work productivity (WP) and daily activity.1 DISCOVER-2 (D2), a phase 3 trial of the selective interleukin-23 p19-subunit inhibitor guselkumab…Abstract Number: 1015 • ACR Convergence 2022
Predictors of Nail Response with Guselkumab: A Post Hoc Analysis of the VOYAGE 2 Clinical Trial
Background/Purpose: Understanding factors that impact response to therapy may help improve disease management, clinical outcomes and patient quality of life. Nails are often overlooked in…Abstract Number: 1043 • ACR Convergence 2022
Uveitis in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: Baseline Characteristics and Incidence Rates During Secukinumab and Placebo Comparative Phase: A Post Hoc Analysis
Background/Purpose: Uveitis is one of the most frequently reported extra-musculoskeletal manifestations of axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA).1,2 The prevalence of anterior uveitis is…Abstract Number: 1259 • ACR Convergence 2022
Characteristics of Sacroiliac Joint in Patient with Skin Psoriasis, Without Rheumatological Manifestations: A Controlled Study Using CT Scan
Background/Purpose: Plaque Psoriasis (PsO) is an inflammatory disorder that could be associated with rheumatological manifestations defining Psoriatic arthritis. Moreover, recent studies showed that the presence…Abstract Number: 1501 • ACR Convergence 2022
Comparative Profiling of Serum Protein Biomarkers and Disease Activity Across Various Disease Domains in Patients with Psoriatic Arthritis (PsA)
Background/Purpose: Psoriatic Arthritis (PsA) is a complex, heterogeneous disease with chronic inflammation. Disease manifestations include the peripheral joint inflammation, dactylitis, enthesitis and skin psoriasis. Chronic…Abstract Number: 1613 • ACR Convergence 2022
Diagnostic Delay and Less Intensive Therapy for People with Psoriatic Arthritis Compared with Rheumatoid Arthritis: A Nested Matched Cohort Study from Within the UK National Early Inflammatory Arthritis Audit
Background/Purpose: To compare the time from symptom onset and General Practitioner (GP) presentation to referral and diagnosis for patients with psoriatic arthritis (PsA) to those…Abstract Number: 2116 • ACR Convergence 2022
Assessment of the Ultrasound and Clinical Response to Apremilast Using a Joint-periarticular-nail Ultrasound Index and Clinical Evaluation in Patients with Active Psoriatic Arthritis
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease involving joint and enthesis disease. Ultrasound (US) has demonstrated its useful tool for the diagnosis of…Abstract Number: 2133 • ACR Convergence 2022
Baseline Biomarkers Predict Better Responses to Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in a Phase 2 Trial in Psoriatic Arthritis
Background/Purpose: Deucravacitinib (DEUC) is a novel, oral, selective TYK2 inhibitor with a unique allosteric mechanism of action that has demonstrated efficacy in patients with psoriasis1…Abstract Number: 2150 • ACR Convergence 2022
Cycling vs Swapping Strategies with TNFi and IL-17i in Psoriatic Arthritis: An Observational Retrospective Monocentric Study
Background/Purpose: The therapy of psoriatic arthritis (PsA) was amplified in the last years with the introduction of a large amount of new biologic molecules with…Abstract Number: 0292 • ACR Convergence 2022
Malignancy in the Upadacitinib Clinical Trial Programs for Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Background/Purpose: Increased risk of malignancies has been associated with chronic inflammation, as well as immunosuppressive and immunomodulatory therapies. The objective of this analysis is to…Abstract Number: 0510 • ACR Convergence 2022
MACE and VTE Across Upadacitinib Clinical Trial Programs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Background/Purpose: Patients with untreated immune-mediated inflammatory diseases, such as RA, PsA, and AS, are at increased risk for major adverse cardiovascular events (MACE) and venous…Abstract Number: 1017 • ACR Convergence 2022
Minimal Important Difference (MID), Minimal Detectable Change (MDC), and Disease Activity Thresholds for Two Novel Composite Instruments (3VAS, 4VAS) in Patients with Psoriatic Arthritis: Pooled Analysis of Three Phase 3 Studies
Background/Purpose: Though continuous composite measures of disease activity for psoriatic arthritis (PsA) assessment exist, abbreviated measures that are more feasible for screening in routine clinical…Abstract Number: 1044 • ACR Convergence 2022
Combined Biological or Targeted Therapy in Spondyloarthritis: Experience from a Multicenter Case Series in Spain
Background/Purpose: Combined biological or targeted therapy (CBTT) is rarely considered in clinical practice due to contraindication in guidelines, potential safety concerns and high costs. However,…Abstract Number: 1260 • ACR Convergence 2022
Tenderness and Radiographic Progression in Rheumatoid Arthritis and Psoriatic Arthritis
Background/Purpose: In inflammatory arthritis swelling is regarded as a sign of synovitis and is associated with radiographic progression. However, the association of tenderness with radiographic…Abstract Number: 1502 • ACR Convergence 2022
Assessment of Perceptions and Practices Regarding the Collaborative Management of Patients with Psoriatic Arthritis Among US Dermatology and Rheumatology Teams
Background/Purpose: The optimal care of psoriatic arthritis (PsA) requires effective collaboration between rheumatology and dermatology teams. We executed an initiative to identify gaps and inform…
- « Previous Page
- 1
- …
- 28
- 29
- 30
- 31
- 32
- …
- 81
- Next Page »